The group scraps cobolimab, alongside MAbs against PVRIG and CD96.
ApexOnco Front Page
Recent articles
The second-line Litespark-011 and adjuvant Litespark-022 trials are apparently hits.
First-in-human studies include a new pan-KRAS inhibitor and CDK2/4 degrader.
“We need all the capital we can get our hands on," the company states.
Astra/Daiichi have trumped Gilead’s Trodelvy with a lung cancer approval.
Zidesamtinib is having a hard time catching up with Ibtrozi's line-agnostic approval.
Sunmo succeeds in a setting very similar to Starglo's.
Zanzalintinib prevails in all comers, but full data will show if the win was driven by a subgroup.
